Vosol

Infection, Communicable Diseases, Urinary Bladder + 2 more

Treatment

5 FDA approvals

5 Active Studies for Vosol

What is Vosol

Acetic acid

The Generic name of this drug

Treatment Summary

Acetic acid is a chemical found in ethanol and in wood that can be used to treat skin irritation or as a reagent. It can also be used in the form of an otic solution for the ear, which is an antibiotic used to treat bacterial or fungal infections.

Acetic Acid

is the brand name

image of different drug pills on a surface

Vosol Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Acetic Acid

Acetic acid

1979

33

Approved as Treatment by the FDA

Acetic acid, otherwise called Acetic Acid, is approved by the FDA for 5 uses which include External ear infection NOS and Urinary Bladder .

External ear infection NOS

Used to treat External ear infection NOS in combination with Acetic acid

Urinary Bladder

Urethral Catheters

Infection

Communicable Diseases

Used to treat External ear infection NOS in combination with Acetic acid

When to interrupt dosage

The measure of Vosol is dictated by the recognized disorder, including Bacterial infection, Urethral Catheters and Communicable Diseases. The amount additionally fluctuates as per the approach of delivery (e.g. Hemodialysis or Solution - Hemodialysis) outlined in the table beneath.

Condition

Dosage

Administration

Communicable Diseases

, 20.75 mg/mL, 20.65 mg/mL, 2.5 mg/mL, 24.1 mg/mL, 0.02 mL/mL, 0.009 mg/mg, 20.8 mg/mL, 25.0 mg/mL, 2.0 mg/mL, 0.02 mg/mL, 1.5 %, 0.9 mg/mL, 20.0 mg/mL, 0.0092 mg/mg, 0.1 mg/mL, 10.81 mg/mL, 10.8 mg/mL, 8.11 mg/mL, 8.846 mg/mL, 5.41 mg/mL, 6.64 mg/mL, 5.28 mg/mL, 6.635 mg/mL, 36.0 mg/mL, 6.31 mg/mL, 5.4 mg/mL, 8.8 mg/mL, 8.85 mg/mL, 6.82 mg/mL, 6.305 mg/mL, 6.756 mg/mL, 8.1 mg/mL, 8.9 mg/mL, 8.847 mg/mL, 6.6349 mg/mL, 6.3053 mg/mL, 8.107 mg/mL, 0.004 meq/mL, 15.0 mg/mL

Solution, , Solution - Auricular (otic), Auricular (otic), Irrigation, Irrigant - Irrigation, Irrigant, Vaginal, Jelly, Jelly - Vaginal, Liquid, Hemodialysis, Solution - Hemodialysis, Liquid - Hemodialysis, Solution / drops, Topical, Gel - Topical, Gel - Vaginal, Gel, Solution / drops - Auricular (otic), Solution - Topical, Liquid - Topical

Infection

, 20.75 mg/mL, 20.65 mg/mL, 2.5 mg/mL, 24.1 mg/mL, 0.02 mL/mL, 0.009 mg/mg, 20.8 mg/mL, 25.0 mg/mL, 2.0 mg/mL, 0.02 mg/mL, 1.5 %, 0.9 mg/mL, 20.0 mg/mL, 0.0092 mg/mg, 0.1 mg/mL, 10.81 mg/mL, 10.8 mg/mL, 8.11 mg/mL, 8.846 mg/mL, 5.41 mg/mL, 6.64 mg/mL, 5.28 mg/mL, 6.635 mg/mL, 36.0 mg/mL, 6.31 mg/mL, 5.4 mg/mL, 8.8 mg/mL, 8.85 mg/mL, 6.82 mg/mL, 6.305 mg/mL, 6.756 mg/mL, 8.1 mg/mL, 8.9 mg/mL, 8.847 mg/mL, 6.6349 mg/mL, 6.3053 mg/mL, 8.107 mg/mL, 0.004 meq/mL, 15.0 mg/mL

Solution, , Solution - Auricular (otic), Auricular (otic), Irrigation, Irrigant - Irrigation, Irrigant, Vaginal, Jelly, Jelly - Vaginal, Liquid, Hemodialysis, Solution - Hemodialysis, Liquid - Hemodialysis, Solution / drops, Topical, Gel - Topical, Gel - Vaginal, Gel, Solution / drops - Auricular (otic), Solution - Topical, Liquid - Topical

Urinary Bladder

, 20.75 mg/mL, 20.65 mg/mL, 2.5 mg/mL, 24.1 mg/mL, 0.02 mL/mL, 0.009 mg/mg, 20.8 mg/mL, 25.0 mg/mL, 2.0 mg/mL, 0.02 mg/mL, 1.5 %, 0.9 mg/mL, 20.0 mg/mL, 0.0092 mg/mg, 0.1 mg/mL, 10.81 mg/mL, 10.8 mg/mL, 8.11 mg/mL, 8.846 mg/mL, 5.41 mg/mL, 6.64 mg/mL, 5.28 mg/mL, 6.635 mg/mL, 36.0 mg/mL, 6.31 mg/mL, 5.4 mg/mL, 8.8 mg/mL, 8.85 mg/mL, 6.82 mg/mL, 6.305 mg/mL, 6.756 mg/mL, 8.1 mg/mL, 8.9 mg/mL, 8.847 mg/mL, 6.6349 mg/mL, 6.3053 mg/mL, 8.107 mg/mL, 0.004 meq/mL, 15.0 mg/mL

Solution, , Solution - Auricular (otic), Auricular (otic), Irrigation, Irrigant - Irrigation, Irrigant, Vaginal, Jelly, Jelly - Vaginal, Liquid, Hemodialysis, Solution - Hemodialysis, Liquid - Hemodialysis, Solution / drops, Topical, Gel - Topical, Gel - Vaginal, Gel, Solution / drops - Auricular (otic), Solution - Topical, Liquid - Topical

Otitis Externa

, 20.75 mg/mL, 20.65 mg/mL, 2.5 mg/mL, 24.1 mg/mL, 0.02 mL/mL, 0.009 mg/mg, 20.8 mg/mL, 25.0 mg/mL, 2.0 mg/mL, 0.02 mg/mL, 1.5 %, 0.9 mg/mL, 20.0 mg/mL, 0.0092 mg/mg, 0.1 mg/mL, 10.81 mg/mL, 10.8 mg/mL, 8.11 mg/mL, 8.846 mg/mL, 5.41 mg/mL, 6.64 mg/mL, 5.28 mg/mL, 6.635 mg/mL, 36.0 mg/mL, 6.31 mg/mL, 5.4 mg/mL, 8.8 mg/mL, 8.85 mg/mL, 6.82 mg/mL, 6.305 mg/mL, 6.756 mg/mL, 8.1 mg/mL, 8.9 mg/mL, 8.847 mg/mL, 6.6349 mg/mL, 6.3053 mg/mL, 8.107 mg/mL, 0.004 meq/mL, 15.0 mg/mL

Solution, , Solution - Auricular (otic), Auricular (otic), Irrigation, Irrigant - Irrigation, Irrigant, Vaginal, Jelly, Jelly - Vaginal, Liquid, Hemodialysis, Solution - Hemodialysis, Liquid - Hemodialysis, Solution / drops, Topical, Gel - Topical, Gel - Vaginal, Gel, Solution / drops - Auricular (otic), Solution - Topical, Liquid - Topical

Urethral Catheters

, 20.75 mg/mL, 20.65 mg/mL, 2.5 mg/mL, 24.1 mg/mL, 0.02 mL/mL, 0.009 mg/mg, 20.8 mg/mL, 25.0 mg/mL, 2.0 mg/mL, 0.02 mg/mL, 1.5 %, 0.9 mg/mL, 20.0 mg/mL, 0.0092 mg/mg, 0.1 mg/mL, 10.81 mg/mL, 10.8 mg/mL, 8.11 mg/mL, 8.846 mg/mL, 5.41 mg/mL, 6.64 mg/mL, 5.28 mg/mL, 6.635 mg/mL, 36.0 mg/mL, 6.31 mg/mL, 5.4 mg/mL, 8.8 mg/mL, 8.85 mg/mL, 6.82 mg/mL, 6.305 mg/mL, 6.756 mg/mL, 8.1 mg/mL, 8.9 mg/mL, 8.847 mg/mL, 6.6349 mg/mL, 6.3053 mg/mL, 8.107 mg/mL, 0.004 meq/mL, 15.0 mg/mL

Solution, , Solution - Auricular (otic), Auricular (otic), Irrigation, Irrigant - Irrigation, Irrigant, Vaginal, Jelly, Jelly - Vaginal, Liquid, Hemodialysis, Solution - Hemodialysis, Liquid - Hemodialysis, Solution / drops, Topical, Gel - Topical, Gel - Vaginal, Gel, Solution / drops - Auricular (otic), Solution - Topical, Liquid - Topical

Warnings

Vosol has two impediments. If you have any of the conditions specified in the following table, Vosol should not be utilized.

Vosol Contraindications

Condition

Risk Level

Notes

use during transurethral surgical procedures

Do Not Combine

Tympanic Membrane Perforation

Do Not Combine

There are 18 known major drug interactions with Vosol.

Common Vosol Drug Interactions

Drug Name

Risk Level

Description

Vibrio cholerae CVD 103-HgR strain live antigen

Major

The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Acetic acid.

Typhoid vaccine

Minor

The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Acetic acid.

(R)-warfarin

Moderate

The risk or severity of bleeding can be increased when Acetic acid is combined with (R)-warfarin.

(S)-Warfarin

Moderate

The risk or severity of bleeding can be increased when Acetic acid is combined with (S)-Warfarin.

4-hydroxycoumarin

Moderate

The risk or severity of bleeding can be increased when Acetic acid is combined with 4-hydroxycoumarin.

image of a doctor in a lab doing drug, clinical research

Vosol Novel Uses: Which Conditions Have a Clinical Trial Featuring Vosol?

16 active studies are currently exploring the potential of Vosol to combat Communicable Diseases, Infections and Urinary Bladder disorders.

Condition

Clinical Trials

Trial Phases

Urinary Bladder

0 Actively Recruiting

Otitis Externa

0 Actively Recruiting

Infection

6 Actively Recruiting

Not Applicable, Phase 1

Communicable Diseases

0 Actively Recruiting

Urethral Catheters

0 Actively Recruiting

Vosol Reviews: What are patients saying about Vosol?

5

Patient Review

9/27/2009

Vosol for Outer Ear Inflammation caused by Allergy or Infection

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about vosol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Vosol antibacterial?

"The clinical pharmacology of Vosol indicates that acetic acid is antibacterial and antifungal, while propylene glycol is hydrophilic and provides a low surface tension. Benzethonium chloride is a surface active agent that promotes contact of the solution with tissues."

Answered by AI

What is Vosol HC used for?

"This medication is a combination of two drugs, acetic acid and hydrocortisone, which are used to treat outer ear infections. Acetic acid kills bacteria and fungus, while hydrocortisone is a steroid that decreases the redness, swelling, and itching associated with the infection."

Answered by AI

What is Vosol?

"Vosol is an antibiotic that treats infections caused by bacteria or fungus. Vosol (for the ear) is used to treat infections in the ear canal. Vosol will not treat an inner ear infection (also called otitis media)."

Answered by AI

Is Vosol a prescription?

"If you experience a temporary stinging or burning sensation in your ear canal, tell your doctor or pharmacist. This medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects."

Answered by AI

Clinical Trials for Vosol

Image of National Institutes of Health Clinical Center in Bethesda, United States.

gp91 Grans for Chronic Granulomatous Disease

18 - 75
Male
Bethesda, MD

Background: CGD is caused by a gene mutation. For people with CGD, their cells cannot kill germs well, so they can get frequent or life-threatening infections. Researchers want to see if a new procedure can help a person s cells kill germs for a short time. It uses messenger RNA (mRNA) to deliver correct instructions for the gene mutation to the cells. Objective: To test a procedure in which mRNA is added to a person s blood cells. Eligibility: Males aged 18-75 with CGD with a mutation in the gene that makes the protein gp91phox. Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Swab to test for strep throat Some screening tests will be repeated during the study. Participants will be admitted to the NIH Clinical Center hospital for at least 7 days. They will have apheresis. For this, a medicine is injected under their skin to prepare their white blood cells for collection. An IV line is placed into an arm vein. Blood goes through the IV line into a machine that divides whole blood into red blood cells, plasma, and white blood cells. The white blood cells are removed, and the rest of the blood is returned to the participant through an IV line in their other arm. The next day, they will get their mRNA-corrected cells via IV. They will be monitored for 3 more days. After discharge, participants will keep a symptom diary. They will be contacted weekly for one month, and then once a month. They will have a follow-up visit 3 months after the infusion.

Phase 1
Recruiting

National Institutes of Health Clinical Center

Suk S De Ravin, M.D.

Image of University of Iowa in Iowa City, United States.

Improved Perioperative Preventive Measures for Surgical Site Infections

18+
All Sexes
Iowa City, IA

Surgical site infections (SSIs) are associated with increased patient morbidity, mortality, and healthcare costs. ESKAPE (Enterococcus, S. aureus, Klebsiella, Acinetobacter, Pseudomonas, and Enterobacter spp.) pathogens are particularly pathogenic because they have increased capacity to acquire resistance and virulence traits. The investigators have proven that a multifaceted program involving improved basic perioperative preventive measures can generate substantial reductions in S. aureus transmission and significant reductions in SSIs (88% reduction as compared to usual care). In this study, the investigators aim to examine the relative effectiveness of each component of this program in controlling ESKAPE transmission and reducing SSIs and to identify an optimal implementation strategy for national dissemination. Randomization occurs at the site level, and sites adopt preventative programs. This work will improve perioperative patient safety for the 51 million patients who undergo surgery each year.

Recruiting
Has No Placebo

University of Iowa (+2 Sites)

Jeremiah R Brown, PhD

Image of University of Ottawa Heart Institute in Ottawa, Canada.

Barrier Dressing for Infections

18+
All Sexes
Ottawa, Canada

This study will evaluate the effect of an iodine impregnated barrier dressing on device pocket swab culture positivity. Minimizing contamination during the implant procedure can be one of the potential improvements to prevent CIED infections. Patients requiring a lead change, battery change or device upgrade will be eligible. This is a randomized, blinded study where participants will be randomized to having the barrier dressing applied before any incision is made (experimental group) or applying the dressing just prior to collecting the culture swab (control group). Patients and the staff taking the culture swab at the end of the procedure are blinded as to which group the participant is randomized to.

Waitlist Available
Has No Placebo

University of Ottawa Heart Institute

Alper Aydin, Dr.

Have you considered Vosol clinical trials?

We made a collection of clinical trials featuring Vosol, we think they might fit your search criteria.
Go to Trials